About
Anti-CSF1 Monoclonal Antibody
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyBiotech
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
6
As Collaborator
0
Total Enrollment
177
By Phase
PHASE2: 4PHASE1/PHASE2: 1PHASE1: 1
By Status
COMPLETED: 4WITHDRAWN: 1TERMINATED: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT05349760Lead Sponsor
A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis
PHASE2Withdrawn
Started: Mar 31, 2023 · Completed: Jun 30, 2025
NCT05349643Lead Sponsor
A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
PHASE2Completed
20 participants
Started: Jan 26, 2023 · Completed: Jun 3, 2024
NCT04938180Lead Sponsor
A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients
PHASE2Terminated
4 participants
Started: Sep 16, 2021 · Completed: May 17, 2022
NCT04731675Lead Sponsor
An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee
PHASE2Completed
11 participants
Started: May 25, 2021 · Completed: May 5, 2022
NCT02713529Lead Sponsor
Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer
PHASE1/PHASE2Completed
117 participants
Started: Apr 14, 2016 · Completed: May 17, 2019
Locations (1)
Headquarters
Redwood City, CA, United States
Map
Loading map...